Peeling R W, Kimani J, Plummer F, Maclean I, Cheang M, Bwayo J, Brunham R C
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
J Infect Dis. 1997 May;175(5):1153-8. doi: 10.1086/516454.
To determine whether serum antibody to Chlamydia trachomatis antigens alters the risk of C. trachomatis pelvic inflammatory disease (PID), 280 female sex workers were prospectively evaluated over a 33-month period for incident C. trachomatis and Neisseria gonorrhoeae cervical infection and for clinical PID. At enrollment, women were tested for antibody to C. trachomatis elementary bodies by an indirect microimmunofluorescence assay and to recombinant chlamydial hsp60 (Chsp60) by an ELISA format. At each follow-up visit, women were tested for cervical chlamydial and gonococcal infection and were identified as having clinical PID if they complained of lower abdominal pain and were found to have uterine and adnexal tenderness on pelvic examination. The data demonstrate that antibody to Chsp60 predicts a 2- to 3-fold increased risk for C. trachomatis PID.
为了确定沙眼衣原体抗原的血清抗体是否会改变沙眼衣原体盆腔炎（PID）的风险，在33个月的时间里，对280名女性性工作者进行了前瞻性评估，以了解沙眼衣原体和淋病奈瑟菌宫颈感染的发病情况以及临床PID情况。在入组时，通过间接微量免疫荧光试验检测女性针对沙眼衣原体原体的抗体，并通过ELISA法检测针对重组衣原体热休克蛋白60（Chsp60）的抗体。在每次随访时，检测女性的宫颈衣原体和淋球菌感染情况，如果她们主诉下腹部疼痛且在盆腔检查中发现子宫和附件有压痛，则被判定为患有临床PID。数据表明，针对Chsp60的抗体预示着沙眼衣原体PID的风险增加2至3倍。
